CoChat
Sign Up
Cited by 35Mesenchymal stem cell researchGlioma Diagnosis and TreatmentBacterial Cancer Therapy

The DOI matches its Crossref record.

Bone marrow-derived mesenchymal stem cells co-expressing interleukin-18 and interferon-β exhibit potent antitumor effect against intracranial glioma in rats

Open access
XU, GANG, GUO, YANWU, SENG, ZHIYUAN, CUI, GANG, QU, JIANQIANG·2015·Oncology Reports
DOI 10.3892/or.2015.4174
Open this paper in CoChat — free accountOpen PDF

Abstract

Bone marrow-derived mesenchymal stem cells (BMSCs) are promising gene vehicles for cancer gene therapy. In our previous study, we reported that BMSCs expressing interleukin (IL)-18 effectively inhibit the growth of glioma in rats. In the present study, we further detected the effect of BMSCs co-expressing IL-18 and interferon (IFN)-β, both of which are immunostimulatory cytokines. BMSCs were genetically engineered to express IL-18 and IFN-β by transfection of recombinant lentivirus-mediated gene transfer. Results showed that BMSCs co-expressing the two cytokines displayed more significant inhibition effect on glioma cell growth in vitro when compared with BMSCs solely expressing IL-18 or IFN-β. Treatment of BMSCs co-expressing IL-18 and IFN-β significantly prolonged the survival and inhibited tumor growth in a rat intracranial glioma model. Furthermore, these genetically engineered BMSCs remarkably promoted cell apoptosis, antitumor cytokine production and CD4+ and CD8+ T-cell infiltration in intracranial glioma tissues than BMSCs solely expressing IL-18 or IFN-β. Results of the present study suggested that IL-18 and IFN-β had a synergistic effect on glioma inhibition. Moreover, results provided evidence that delivery of IL-18 and IFN-β by BMSCs may be an excellent and promising approach to develop an effective treatment protocol for glioma therapy.

Overview

Integrity signals

Registry

Crossref · 10.3892/or.2015.4174

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Research works printed but not linked: 45

  1. Mao, 2009, Progress on potential strategies to target brain tumor stem cells, Cell Mol Neurobiol, 29, 141, 10.1007/s10571-008-9310-1 · DOI
  2. Maher, 2001, Malignant glioma: Genetics and biology of a grave matter, Genes Dev, 15, 1311, 10.1101/gad.891601 · DOI
  3. Sanai, 2008, Glioma extent of resection and its impact on patient outcome, Neurosurgery, 62, 753, 10.1227/01.neu.0000318159.21731.cf · DOI
  4. Bexell, 2009, Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas, Mol Ther, 17, 183, 10.1038/mt.2008.229 · DOI
  5. Gunnarsson, 2010, Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immuno-therapy of experimental glioma, J Neuroimmunol, 218, 140, 10.1016/j.jneuroim.2009.10.017 · DOI
  6. Matuskova, 2010, HSV-tk expressing mesenchymal stem cells exert bystander effect on human glio-blastoma cells, Cancer Lett, 290, 58, 10.1016/j.canlet.2009.08.028 · DOI
  7. Suryadevara, 2015, Immunotherapy for malignant glioma, Surg Neurol Int, 6, S68, 10.4103/2152-7806.151341 · DOI
  8. Okamura, 1995, Cloning of a new cytokine that induces IFN-gamma production by T cells, Nature, 378, 88, 10.1038/378088a0 · DOI
  9. Hwang, 2004, Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity, Cancer Gene Ther, 11, 397, 10.1038/sj.cgt.7700711 · DOI
  10. Ossendorp, 1998, Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors, J Exp Med, 187, 693, 10.1084/jem.187.5.693 · DOI
  11. Kohyama, 1998, Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18, Jpn J Cancer Res, 89, 1041, 10.1111/j.1349-7006.1998.tb00494.x · DOI
  12. Xia, 2004, Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity, Cancer Biother Radiopharm, 19, 322, 10.1089/1084978041424990 · DOI
  13. Glick, 1997, Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma, Neurosurgery, 41, 898, 10.1097/00006123-199710000-00025 · DOI
  14. Sobol, 1995, Interleukin-2 gene therapy in a patient with glioblastoma, Gene Ther, 2, 164
  15. Hertzog, 1994, Role of interferons in the regulation of cell proliferation, differentiation, and development, Mol Reprod Dev, 39, 226, 10.1002/mrd.1080390216 · DOI
  16. Nakahara, 2003, Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells, Cancer Gene Ther, 10, 549, 10.1038/sj.cgt.7700598 · DOI
  17. Williams, 2010, Targeting multiple angiogenic pathways for the treatment of neuroblastoma, J Pediatr Surg, 45, 1103, 10.1016/j.jpedsurg.2010.02.073 · DOI
  18. Kageshita, 2001, Growth inhibition of human malignant melanoma transfected with the human interferon-beta gene by means of cationic liposomes, Melanoma Res, 11, 337, 10.1097/00008390-200108000-00003 · DOI
  19. Natsume, 1999, Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse, Gene Ther, 6, 1626, 10.1038/sj.gt.3300990 · DOI
  20. Natsume, 2000, IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma, J Neurooncol, 47, 117, 10.1023/A:1006441030976 · DOI
  21. Xu, 2009, Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats, Cell Biol Int, 33, 466, 10.1016/j.cellbi.2008.07.023 · DOI
  22. Olson, 1990, Enhancement of the efficacy of x-irradiation by pentobarbital in a rodent brain-tumor model, J Neurosurg, 72, 745, 10.3171/jns.1990.72.5.0745 · DOI
  23. Farrell, 1987, A new glioma model in rat: The C6 spheroid implantation technique permeability and vascular characterization, J Neurooncol, 4, 403, 10.1007/BF00195612 · DOI
  24. Chen, 2006, Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells, Eur J Immunol, 36, 1598, 10.1002/eji.200535501 · DOI
  25. Lohr, 2011, Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β, Clin Cancer Res, 17, 4296, 10.1158/1078-0432.CCR-10-2557 · DOI
  26. Kraman, 2010, Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha, Science, 330, 827, 10.1126/science.1195300 · DOI · Paper page
  27. Nakamizo, 2005, Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas, Cancer Res, 65, 3307, 10.1158/0008-5472.CAN-04-1874 · DOI
  28. Uchibori, 2009, Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy, J Gene Med, 11, 373, 10.1002/jgm.1313 · DOI
  29. Menon, 2009, Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy, Stem Cells, 27, 2320, 10.1002/stem.136 · DOI
  30. Tang, 2014, TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells, Anticancer Res, 34, 729
  31. Liu, 2012, Overexpression of interleukin-18 induces growth inhibition, apoptosis and gene expression changes in a human tongue squamous cell carcinoma cell line, J Int Med Res, 40, 537, 10.1177/147323001204000215 · DOI
  32. Liu, 2015, Overexpression of interleukin-18 protein reduces viability and induces apoptosis of tongue squamous cell carcinoma cells by activation of glycogen synthase kinase-3β signaling, Oncol Rep, 33, 1049, 10.3892/or.2015.3724 · DOI
  33. Zheng, 2010, Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis, Cancer Gene Ther, 17, 28, 10.1038/cgt.2009.38 · DOI
  34. Takano, 2014, Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10, Int J Oncol, 45, 1837, 10.3892/ijo.2014.2620 · DOI
  35. Yoshida, 1992, Cytotoxicity of human beta-interferon produced in human glioma cells transfected with its gene by means of liposomes, Biochem Int, 28, 1055
  36. Guo, 2012, Induction of apoptosis in glioma cells and upregulation of Fas expression using the human interferon-β gene, Asian Pac J Cancer Prev, 13, 2837, 10.7314/APJCP.2012.13.6.2837 · DOI
  37. Zhang, 2004, C6 glioma cells retrovi-rally engineered to express IL-18 and Fas exert FasL-dependent cytotoxicity against glioma formation, Biochem Biophys Res Commun, 325, 1240, 10.1016/j.bbrc.2004.10.165 · DOI
  38. Marshall, 2006, Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine, Vaccine, 24, 244, 10.1016/j.vaccine.2005.07.087 · DOI
  39. Robertson, 2006, Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer, Clin Cancer Res, 12, 4265, 10.1158/1078-0432.CCR-06-0121 · DOI
  40. Kikuchi, 2000, Antitumor activity of interleukin-18 on mouse glioma cells, J Immunother, 23, 184, 10.1097/00002371-200003000-00002 · DOI
  41. Yamanaka, 2005, Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18, DNA Cell Biol, 24, 317, 10.1089/dna.2005.24.317 · DOI
  42. Yamanaka, 2005, Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma, J Neurooncol, 72, 107, 10.1007/s11060-004-3550-9 · DOI
  43. Yamanaka, 2003, Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12, J Neurosurg, 99, 746, 10.3171/jns.2003.99.4.0746 · DOI
  44. Meijer, 2009, Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta, Cancer Gene Ther, 16, 664, 10.1038/cgt.2009.8 · DOI
  45. Streck, 2006, Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta, Cancer Gene Ther, 13, 99, 10.1038/sj.cgt.7700878 · DOI

Cited by

Metadata

Authors
XU, G., GUO, Y., SENG, Z., CUI, G., & QU, J.
Affiliations
  • Second Affiliated Hospital of Xi'an Jiaotong University (CN)
  • Zhujiang Hospital (CN)
ORCID
Venue
Oncology Reports
Publisher
Spandidos Publications
Published
2015-08-05
Volume
34
Issue
4
Pages
1915-1922
ISSN
  • 1021-335X (ISSN-L)
  • 1791-2431
DOI
10.3892/or.2015.4174
OpenAlex
W2144749165
Cited by
35
References
0
Citations by year
2025: 1 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 5 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 2 · 2016: 3
FWCI
1.68
Type
journal article
Language
en
Open access
Locations
  • Oncology Reports (publishedVersion)
  • PubMed (publishedVersion)
Funders
Natural Science Foundation of Shaanxi Province
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
bone marrow-derived mesenchymal stem cells, IL-18, interferon-beta, intracranial glioma, cancer gene therapy, lentivirus-mediated gene transfer, tumor growth inhibition, T cell infiltration, apoptosis, antitumor cytokines, cytokine synergy
MeSH terms
Animals, Bone Marrow Cells, Brain Neoplasms, Disease Models, Animal, Glioma, Humans, Genetic Therapy, Interferon-beta, Interleukin-18, Mesenchymal Stem Cell Transplantation, Rats, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review